Tolvaptan for the treatment of hyponatremia and congestive heart failure

Future Cardiology

Volumn 2, Issue 6, 2006, Pages 627-634

  Orlandi, Cesare ^a   Zimmer, Christopher A ^a   Gheorghiade, Mihai ^b  

^a OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Aquaresis; Arginine; Congestive heart failure; Hyponatremia; Tolvaptan; Vasopressin

Indexed keywords

AMIODARONE; ARGIPRESSIN RECEPTOR; KETOCONAZOLE; SODIUM; TOLVAPTAN; WARFARIN;

ADD ON THERAPY; ARTICLE; BLOOD PRESSURE; CARDIAC PATIENT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEHYDRATION; DETERIORATION; DIZZINESS; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; EDEMA; FATIGUE; HEART RATE; HOSPITALIZATION; HUMAN; HYPONATREMIA; KIDNEY FUNCTION; MYALGIA; POLLAKISURIA; PRIORITY JOURNAL; SIDE EFFECT; SODIUM BLOOD LEVEL; THIRST; WEIGHT REDUCTION; XEROSTOMIA;

EID: 33750973933     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/14796678.2.6.627     Document Type: Article

References (19)

1. 1a arginine vasopressin receptor. Nature 356, 523-526 (1992).
2. Thibonnier M, Auzan C, Madhun Z, Wilkins P, Berti-Mattera L, Clauser E: Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor. J. Biol. Chem. 269, 3304-3310 (1994).
3. 3 pituitary vasopressin receptor. FEBS Lett. 356, 215-220 (1994).
4. 1b vasopressin receptor. J. Biol. Chem. 269, 27088-27092 (1994).
5. Birnbaumer M, Seibold A, Gilbert S et al.: Molecular cloning of the receptor for human antidiuretic hormone. Nature 357, 333-335 (1992).
6. 2 receptor and possible link to nephrogenic diabetes insipidus. Nature 357, 336-339 (1992).
7. 2 receptor antagonists. J. Mol. Endocrinol. 29, 1-9 (2002).
8. Anderson RJ, Chung H, Kluge R, Schrier RW: Hyponatremia: a prospective analysis of its epidemiology and pathogenetic role of vasopressin. Ann. Intern. Med. 102(2), 164-168 (1985).
9. Palmer BF: Potassium disturbances associated with the use of diuretics. In: Diuretic agents - Clinical Physiology and Pharmacology. Seldin D, Giebisch G (Eds.) Academic Press Inc., San Diego, CA, USA 571-583 (1997).
10. Rivera-Santos A, Star R: Sodium: volume depletion and hyponatremia. In: Diuretic agents - Clinical Physiology and Pharmacology. Seldin D, Giebisch G (Eds.) Academic Press Inc., San Diego, CA, USA 559-569 (1997).
11. 2 receptor antagonist. Bioorg. Med. Chem. 7, 1743-1754 (1999).
12. Gheorghiade M, Teerlink JR, Mebazaa A: Pharmacology of new agents for acute heart failure syndromes. Am. J. Cardiol. 96(Suppl.), G68-G73 (2005).
13. Shoaf SE, Elizari MV, Wang Z et al.: Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias. J. Cardiovasc. Pharmacol. Therapeut. 10(3), 165-171 (2005).
14. 2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 107, 2690-2696 (2003).
15. Gheorghiade M, Gattis WA, O'Connor CM et al.: Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 291(16), 1963-1971 (2004).
16. 2 Receptor Antagonist, Tolvaptan, on the Long-term Progression of Left Ventricular Dilatation in Patients with Heart Failure. Circulation 112, II-504 (2005) (Abstract).
17. Costello-Boerrigter LC, Smith WB, Boerringter G et al.: Vasopressin 2 receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am. J. Physiol. Renal. Physiol. 290(2), F273-F278 (2005).
18. 2 receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am. J. Cardiol. 97, 1064-1067 (2006).
19. Gheorghiade M, Orlandi C, Burnett Jr JC et al.: Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure: outcome study with tolvaptan (EVEREST). J. Card. Fail. 11(4), 260-269 (2005).